Author

Gerard Dijkstra

RELIABILITY AND RELATIVE CONSTRUCT VALIDITY OF A FOOD FREQUENCY QUESTIONNAIRE: THE GRONINGEN INFLAMMATORY BOWEL DISEASE NUTRITIONAL QUESTIONNAIRES (GINQ-FFQ)
RELIABILITY AND RELATIVE CONSTRUCT VALIDITY OF A FOOD FREQUENCY QUESTIONNAIRE: THE GRONINGEN INFLAMMATORY BOWEL DISEASE NUTRITIONAL QUESTIONNAIRES (GINQ-FFQ)

Gerard Dijkstra  et al.

RISK ASSESSMENT FOR POSTOPERATIVE RECURRENCE AFTER ILEOCOLONIC RESECTION IN CROHN'S DISEASE (ON BEHALF OF THE DUTCH INITIATIVE ON CROHN AND COLITIS (ICC)
RISK ASSESSMENT FOR POSTOPERATIVE RECURRENCE AFTER ILEOCOLONIC RESECTION IN CROHN'S DISEASE (ON BEHALF OF THE DUTCH INITIATIVE ON CROHN AND COLITIS (ICC)

Gerard Dijkstra  et al.

PREHABILITATION STRATEGIES PRIOR TO ILEOCOLIC (RE-)RESECTION IN PATIENTS WITH CROHN’S DISEASE: A MISSED WINDOW OF OPPORTUNITY?
PREHABILITATION STRATEGIES PRIOR TO ILEOCOLIC (RE-)RESECTION IN PATIENTS WITH CROHN’S DISEASE: A MISSED WINDOW OF OPPORTUNITY?

Gerard Dijkstra  et al.

POSTOPERATIVE PROPHYLACTIC THIOPURINES OR BIOLOGICALS ARE PROTECTIVE FOR CLINICAL AND ENDOSCOPIC RECURRENCE AT SHORT TERM FOLLOW-UP AFTER PRIMARY ILEOCECAL RESECTION IN CROHN'S DISEASE, BUT NOT ASSOCIATED WITH A LONG-TERM BENEFICIAL EFFECT ON THE RISK OF
POSTOPERATIVE PROPHYLACTIC THIOPURINES OR BIOLOGICALS ARE PROTECTIVE FOR CLINICAL AND ENDOSCOPIC RECURRENCE AT SHORT TERM FOLLOW-UP AFTER PRIMARY ILEOCECAL RESECTION IN CROHN'S DISEASE, BUT NOT ASSOCIATED WITH A LONG-TERM BENEFICIAL EFFECT ON THE RISK OF

Gerard Dijkstra  et al.

THE INTERACTION OF GENETIC VARIANTS AND TOBACCO SMOKING IN CROHN’S DISEASE AND ULCERATIVE COLITIS: A GENOME WIDE STUDY
THE INTERACTION OF GENETIC VARIANTS AND TOBACCO SMOKING IN CROHN’S DISEASE AND ULCERATIVE COLITIS: A GENOME WIDE STUDY

Gerard Dijkstra  et al.

GUT MICROBIAL CHANGES IN RESPONSE TO VEDOLIZUMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
GUT MICROBIAL CHANGES IN RESPONSE TO VEDOLIZUMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

TIME TRENDS FOR POSTOPERATIVE RECURRENCE AFTER ILEOCECAL RESECTION IN CROHN'S DISEASE: DETAILED EVALUATION OF ASSOCIATED FACTORS
TIME TRENDS FOR POSTOPERATIVE RECURRENCE AFTER ILEOCECAL RESECTION IN CROHN'S DISEASE: DETAILED EVALUATION OF ASSOCIATED FACTORS

Gerard Dijkstra  et al.

FAECALIBACTERIUM PRAUSNITZII MODULATES INTESTINAL MUCOSAL HEALTH VIA HIF1ALPHA-INDUCED EPITHELIAL PRODUCTION OF IL-18
FAECALIBACTERIUM PRAUSNITZII MODULATES INTESTINAL MUCOSAL HEALTH VIA HIF1ALPHA-INDUCED EPITHELIAL PRODUCTION OF IL-18

Gerard Dijkstra  et al.

TNF?-ANTAGONIST USE AND MUCOSAL INFLAMMATION ARE ASSOCIATED WITH INCREASED INTESTINAL EXPRESSION OF SARS-COV-2 HOST PROTEASE TMPRSS2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
TNF?-ANTAGONIST USE AND MUCOSAL INFLAMMATION ARE ASSOCIATED WITH INCREASED INTESTINAL EXPRESSION OF SARS-COV-2 HOST PROTEASE TMPRSS2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

ANTI-INFLAMMATORY ACTIONS OF BUTYRATE ON MACROPHAGES AND EPITHELIAL CELLS IN INTESTINAL MUCOSA OF INFLAMMATORY BOWEL DISEASE PATIENTS
ANTI-INFLAMMATORY ACTIONS OF BUTYRATE ON MACROPHAGES AND EPITHELIAL CELLS IN INTESTINAL MUCOSA OF INFLAMMATORY BOWEL DISEASE PATIENTS

Gerard Dijkstra  et al.

PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE
PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

THE EFFECT OF RIBOFLAVIN SUPPLEMENTATION ON THE SYSTEMIC REDOX STATUS IN HEALTHY VOLUNTEERS: A POST-HOC ANALYSIS OF THE RIBOGUT TRIAL
THE EFFECT OF RIBOFLAVIN SUPPLEMENTATION ON THE SYSTEMIC REDOX STATUS IN HEALTHY VOLUNTEERS: A POST-HOC ANALYSIS OF THE RIBOGUT TRIAL

Gerard Dijkstra  et al.

INVESTIGATION OF SOMATIC MUTATIONS IN BIOPSIES FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE
INVESTIGATION OF SOMATIC MUTATIONS IN BIOPSIES FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

USE OF TUMOR NECROSIS FACTOR-ALPHA ANTAGONISTS IS ASSOCIATED WITH ATTENUATED IGG ANTIBODY RESPONSE AGAINST SARS-COV-2 IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
USE OF TUMOR NECROSIS FACTOR-ALPHA ANTAGONISTS IS ASSOCIATED WITH ATTENUATED IGG ANTIBODY RESPONSE AGAINST SARS-COV-2 IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

INULIN-GROWN FAECALIBACTERIUM PRAUSNITZII CROSS-FEEDS THE HUMAN INTESTINAL EPITHELIUM WITH FRUCTOSE
INULIN-GROWN FAECALIBACTERIUM PRAUSNITZII CROSS-FEEDS THE HUMAN INTESTINAL EPITHELIUM WITH FRUCTOSE

Gerard Dijkstra  et al.

INTRAVENOUS ADMINISTRATION OF FLUORESCENTLY LABELLED VEDOLIZUMAB TO GAIN INSIGHT IN LOCAL DRUG DISTRIBUTION AND PHARMACODYNAMICS IN INFLAMMATORY BOWEL DISEASE DURING ENDOSCOPY
INTRAVENOUS ADMINISTRATION OF FLUORESCENTLY LABELLED VEDOLIZUMAB TO GAIN INSIGHT IN LOCAL DRUG DISTRIBUTION AND PHARMACODYNAMICS IN INFLAMMATORY BOWEL DISEASE DURING ENDOSCOPY

Gerard Dijkstra  et al.

SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY
SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY

Gerard Dijkstra  et al.

SYSTEMIC IRON DEFICIENCY AND INTESTINAL INFLAMMATION CONTROL GUT MUCOSAL HIF-1? AND TFRC ACTIVATION IN INFLAMMATORY BOWEL DISEASE
SYSTEMIC IRON DEFICIENCY AND INTESTINAL INFLAMMATION CONTROL GUT MUCOSAL HIF-1? AND TFRC ACTIVATION IN INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE
BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE

Gerard Dijkstra  et al.

SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

Item 1 - 20 / 33
1
2